AbbVie: Ruxolitinib has been approved for a new indication in China for the treatment of adult giant cell arteritis.

On June 4th, AbbVie announced that the China National Medical Products Administration has approved RINVOQ for the treatment of adult patients with giant cell arteritis. This approval comes just over a month after its approval in the United States and European Union, making RINVOQ the first and only oral JAK inhibitor approved in China for the treatment of giant cell arteritis in adult patients.